Business Wire

MyHeritage Releases SuperSearch - a State of the Art Search Engine for Family History

25.6.2012 18:27:53 CEST | Business Wire | Press release

Share
UT-MYHERITAGE

Cutting-edge search engine powers breakthrough discoveries, adds color to family history and establishes the popular family network as a leading player in the historical content market

MyHeritage , the most popular family network on the web, today announced the official launch of SuperSearch, a powerful new family history search engine for helping families around the world discover historical records and long-lost relatives. Packed with the industry’s most international source of historical content and family trees, SuperSearch (www.myheritage.com/research ) is capable of searching billions of records within seconds. With a simple and contemporary user experience, clever search features, a massive library of content including one billion global family tree profiles, the world’s largest collection of historical newspapers, and flexible pay-as-you-go or subscription payment options, SuperSearch raises the bar and provides new value and choice for family history fans.

With more than 63 million registered users, MyHeritage has become the trusted home on the web for families wishing to explore their family history, share memories and stay connected. The official launch of SuperSearch, which has been in Beta since April 2012, reaffirms MyHeritage’s position as a leading provider of historical records, following the company’s recent acquisition of WorldVitalRecords and FamilyLink , appointment of former Footnote.com Founder and CEO Russ Wilding to lead content growth, and initiative to provide a free searchable index for the 1940 U.S. Census.

Number one online destination for global research

Available in 38 languages, SuperSearch is the industry’s most multilingual family history search engine, breaking down geographical and language barriers in genealogy research. SuperSearch automatically translates and searches possible initials, synonyms and spelling variations. For example a search for William will also catch Bill, Vilhelm, Guillaume, Guglielmo and many other variations, even when written in other alphabets such as Russian or Hebrew. This increases the chances of finding valuable information within the huge hoards of content on MyHeritage without requiring users to try such variations themselves.

Content highlights

With a powerful mix of historical records and user-generated information in family trees on MyHeritage, SuperSearch helps family history enthusiasts break through brick walls in their research and add color to their family history. The more than 4 billion records on MyHeritage provide worldwide coverage, with strong collections in the USA, UK, Ireland, Australia and Canada. Some record collections are exclusive to MyHeritage, and all this is augmented by content licensed from important third-party databases. Users can find birth, marriage, death, burial, census, military, immigration, yearbooks and other types of records, and view scans of original documents. SuperSearch includes the world’s largest historical newspaper collection (currently about 120 million pages dating back to the 18th century), the 1930 and 1940 US census records, all UK censuses between 1841 and 1901 and the content from MyHeritage-owned family history websites, WorldVitalRecords and FamilyLink .

“SuperSearch represents a watershed innovation in the family history industry,” said Founder and CEO of MyHeritage, Gilad Japhet. “It transforms family history into an experience that is more global, accessible and engaging than ever before. Within a few minutes, you can unravel family mysteries - discover your great-aunt on a passenger list to Ellis Island, find your long-lost branch of the family in a family tree in Brazil or locate the photo of your great-grandfather’s gravestone in England. Complementing our expertise in community family tree building, SuperSearch helps fulfill our goal of connecting families to each other and to their past, and does so in full color, with photos, videos and documents. We're adding millions of new records and family tree profiles every day, which, together with the imminent launch of Record Matching, makes SuperSearch an indispensable tool for family history fans around the world.”

SuperSearch features:

• Easily search for historical records of any person by first name and/or last name, with optional dates or places.

• Search also by keywords, events, relationships and other advanced criteria.

• Find people without even knowing their last names, for example, find three brothers in the same family using only their first names and relationship as siblings, or find all people born on a certain date or in a certain town.

• Run a global search to cover all data collections at once, or drill down to search only in one collection or one category.

• SuperSearch is smart enough to figure out the likely gender of the person you're trying to find.

• Choose between a mode that shows all results, and a summary mode that shows the count of matches from each collection.

• Results arrive fast, typically within a second, ranked by relevance.

• Refine results by collection or by any other common criteria.

For a one-minute summary of SuperSearch, watch the video .

Search on-the-go via MyHeritage mobile app

Users can use SuperSearch on-the-go with the latest version of the MyHeritage Mobile App for iPhone & iPad and Android . With anywhere, anytime access to billions of records, SuperSearch on the MyHeritage App is ideal for introducing family history to friends and family and for fun moments at family reunions.

Access to records

SuperSearch is open to all and requires no registration. Search result lists are displayed for free. Full access to individual records is provided for free for complimentary content, such as the 1940 U.S. Census and the US Social Security Death Index. To access other, paid-only content, MyHeritage gives users maximum choice via affordable pay-as-you-go credits and data subscription plans at prices that are 75% less expensive than competing services.

Coming soon – Record Matching for automatic discoveries

In the coming weeks, MyHeritage will announce the launch of Record Matching on SuperSearch – a powerful and innovative feature that automatically compares family tree profiles and historical records to each other to find matches, with a high degree of accuracy.

About MyHeritage

MyHeritage is the most popular family network on the web. On MyHeritage, millions of families around the world enjoy having a private and free place to explore their history and share special family memories. Pioneers in making family history a collaborative experience for all the family, MyHeritage empowers its users with innovative social tools and a massive library of historical content. The site is available in 38 languages. The company is backed by Accel Partners and Index Ventures, the investors of Facebook and Skype. For more information visit www.myheritage.com .

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50321941&lang=en

Contact:

Press Contact
Caroline Cohen, PR Manager for MyHeritage
Phone: +44 2081231152
Email: caroline@myheritage.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye